Biopsy System

Biopsy System Market Outlook

The global biopsy system market is projected to reach approximately USD 5.2 billion by 2035, growing at a CAGR of 7.2% from 2025 to 2035. This growth can be attributed to several factors, including the increasing prevalence of cancer, the rising demand for minimally invasive diagnostic procedures, and advancements in technology that enhance the efficacy and accuracy of biopsies. Additionally, the growing awareness of early cancer detection and the development of novel biopsy methods, such as liquid biopsies, are contributing to market expansion. The increase in healthcare expenditure and the rising number of cancer screening programs around the world also play essential roles in boosting the market. Furthermore, the integration of artificial intelligence and machine learning in diagnostic processes is expected to enhance the precision and speed of biopsy analysis, thereby driving market growth.

Growth Factor of the Market

Several key factors are driving the biopsy system market, primarily the increasing incidence of cancer globally. With cancer being one of the leading causes of death worldwide, early and accurate diagnosis is critical for effective treatment. The rise in aging populations globally is also significant, as older adults are at a higher risk of developing various forms of cancer. Moreover, advancements in biopsy techniques, such as robotic and MRI-guided biopsies, are revolutionizing the diagnostic process, enabling healthcare providers to obtain more precise tissue samples with less discomfort for patients. The shift towards outpatient settings and minimally invasive procedures further supports market growth, as patients prefer quicker recovery times and reduced hospital stays. Lastly, the enhanced capabilities of liquid biopsies to detect cancer biomarkers with minimal invasiveness are also fostering innovation and interest in the sector.

Key Highlights of the Market

• The biopsy system market is expected to grow at a 7.2% CAGR from 2025 to 2035.
• Needle biopsy is anticipated to remain the dominant product type due to its widespread use and effectiveness.
• North America is projected to hold the largest market share, driven by advanced healthcare infrastructure and high rates of cancer incidence.
• The introduction of robotic-assisted biopsy systems is poised to transform the landscape of biopsy procedures.
• There is a growing trend towards liquid biopsies, which offer less invasive options for cancer detection and monitoring.

By Product Type

Needle Biopsy:

Needle biopsies are among the most commonly used procedures for obtaining tissue samples for diagnostic purposes. This method includes fine needle aspiration (FNA), core needle biopsy (CNB), and vacuum-assisted biopsy (VAB). Needle biopsies are favored for their minimally invasive nature, allowing for sample collection with minimal disruption to surrounding tissues. This approach is particularly effective for cancers located in easily accessible areas, such as the breast, prostate, and thyroid. The market for needle biopsies is expected to witness substantial growth, driven by technological advancements that improve accuracy and decrease complications, alongside the rising awareness of their benefits for early cancer detection.

Surgical Biopsy:

Surgical biopsy involves the removal of a larger portion or an entire tumor for analysis. This method is typically performed when needle biopsies are inconclusive or when a larger tissue sample is necessary to make a diagnosis. Surgical biopsies can either be excisional or incisional, depending on the extent of tissue removal. Although more invasive than needle biopsies, surgical biopsies are vital for obtaining definitive diagnoses in complex cases. This segment is expected to grow as the demand for accurate cancer diagnosis increases, although it may face competition from less invasive biopsy methods that offer faster recovery times for patients.

Liquid Biopsy:

Liquid biopsies represent a groundbreaking development in the field of cancer diagnostics, allowing for the analysis of biomarkers in body fluids, such as blood. This non-invasive procedure can detect the presence of cancer cells or genetic material shed by tumors into the bloodstream. The increasing preference for non-invasive testing methods among patients and clinicians is a major driver for the growth of the liquid biopsy market. Liquid biopsies are particularly useful for monitoring treatment response and detecting minimal residual disease, thus providing invaluable information throughout a patient's treatment journey. As research and technology continue to advance, liquid biopsies are expected to play an integral role in personalized medicine and cancer management.

Robotic Biopsy:

Robotic biopsy systems are an emerging innovation that enhances the precision and control of the biopsy procedure. These systems utilize robotic arms to perform biopsies at exact angles and depths, reducing the risk of error and improving patient outcomes. Robotic biopsy methods are especially beneficial in challenging anatomical locations where traditional methods may be less effective or more invasive. The market for robotic biopsies is anticipated to grow significantly as healthcare providers adopt these advanced technologies to improve their diagnostic capabilities and patient care standards, driven by the demand for accuracy and safety in biopsy procedures.

MRI-Guided Biopsy:

MRI-guided biopsy utilizes magnetic resonance imaging technology to precisely locate and sample suspicious tissue. This technique is particularly useful for lesions that are not easily accessible or detectable by other means, such as ultrasound or CT scans. The ability to visualize the biopsy site in real-time allows for increased accuracy and reduced risk of complications. As the prevalence of prostate and breast cancers rises, the market for MRI-guided biopsies is expected to see significant growth, particularly in regions where advanced imaging technologies are readily available, and medical professionals are trained to use them effectively.

By Application

Breast Biopsy:

Breast biopsies are crucial for diagnosing breast cancer, which remains one of the most common cancers among women globally. This segment includes various techniques, such as needle and surgical biopsies, aimed at obtaining tissue samples from breast lesions. The increasing incidence of breast cancer, coupled with heightened awareness regarding early detection, is expected to drive the demand for breast biopsy procedures significantly. Additionally, advancements in imaging technologies and biopsy methods are enhancing the accuracy and efficiency of these procedures, further contributing to market growth in this segment.

Prostate Biopsy:

Prostate biopsies are primarily performed to diagnose prostate cancer, making them vital in urology. These procedures typically involve needle biopsies guided by ultrasound or MRI to obtain samples from suspicious areas of the prostate gland. With the rise in prostate cancer cases globally, the demand for prostate biopsies is increasing. Furthermore, ongoing research and improvements in biopsy techniques are enhancing diagnostic accuracy, thereby driving the growth of this market segment. As awareness and access to prostate cancer screenings rise, the prostate biopsy market is expected to expand significantly.

Lung Biopsy:

Lung biopsies are performed to assess lung lesions and diagnose various conditions, including lung cancer. Procedures can involve needle biopsies or more invasive surgical approaches, depending on the lesion's location and size. The increase in smoking rates and environmental factors contributing to lung disease have led to a higher incidence of lung cancer, thereby fueling the demand for lung biopsies. With advancements in imaging technologies and minimally invasive techniques, the lung biopsy market is anticipated to witness substantial growth as healthcare providers seek to improve diagnostic accuracy and patient outcomes.

Liver Biopsy:

Liver biopsies are essential for diagnosing liver diseases, including hepatitis, cirrhosis, and liver cancer. They typically involve a needle biopsy procedure to obtain liver tissue samples for analysis. Given the rising prevalence of liver diseases due to factors such as viral infections, alcohol consumption, and obesity, the demand for liver biopsies is increasing. The development of non-invasive alternatives and advancements in imaging techniques are expected to influence this market segment positively, as they enhance the accuracy of liver disease diagnosis and reduce patient discomfort.

Skin Biopsy:

Skin biopsies are performed to diagnose various skin conditions, including melanoma and other skin cancers. This type of biopsy can be conducted through several techniques, including punch biopsies, shave biopsies, and excisional biopsies. With an increasing global incidence of skin cancer due to factors like sun exposure and tanning, the demand for skin biopsies is on the rise. The market for skin biopsies is anticipated to grow as awareness of skin health and the importance of early detection continues to increase, alongside innovations in biopsy techniques that improve patient experiences.

By Distribution Channel

Hospitals:

Hospitals remain the largest distribution channel for biopsy systems, offering comprehensive diagnostic services supported by advanced technology and specialized medical professionals. With significant investments in healthcare infrastructure and diagnostic equipment, hospitals are well-positioned to perform various biopsy procedures. The growing volume of cancer cases requiring biopsy analysis further fuels this segment’s growth. Additionally, hospitals often have access to integrated care systems that facilitate better patient management and follow-up, making them the preferred choice for biopsy procedures.

Diagnostic Centers:

Diagnostic centers are crucial players in the biopsy system market, providing specialized services focused on diagnostic imaging and laboratory testing. These facilities often offer a wide range of biopsy procedures, including needle biopsies and liquid biopsies, catering to various patient needs. The increasing trend toward outpatient care and the convenience offered by diagnostic centers encourage more patients to opt for these facilities for their biopsy needs. As demand for rapid and accurate diagnostic services grows, diagnostic centers are expected to expand their capabilities, thereby driving growth in this segment.

Cancer Research Institutes:

Cancer research institutes play a vital role in advancing biopsy technologies and methodologies, facilitating research and clinical trials to improve cancer diagnostics. These institutions often collaborate with hospitals and diagnostic centers to optimize biopsy procedures and analyze sampled tissues. The focus on precision medicine and personalized treatment is particularly prevalent in research settings, which contributes to the growth of this segment. As the emphasis on research and innovation in cancer care continues to rise, cancer research institutes are poised to become essential players in the biopsy system market.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have gained popularity as they offer outpatient surgical services, including biopsy procedures. The advantages of ASCs, such as lower costs, shorter wait times, and reduced recovery times, make them an attractive option for patients seeking biopsy services. The growing preference for minimally invasive procedures and outpatient care has contributed to the rising demand for ASCs. As more patients opt for procedures that allow them to return home the same day, the market for biopsy systems in ASCs is expected to expand significantly.

Specialty Clinics:

Specialty clinics focus on specific areas of healthcare, including oncology and dermatology, providing targeted biopsy services tailored to particular patient needs. These clinics often employ advanced technologies and techniques to enhance diagnostic accuracy while ensuring a streamlined patient experience. The increasing incidence of various cancers and skin disorders is driving the demand for specialized care, leading to growth in this segment. Specialty clinics are expected to expand their biopsy offerings, thereby catering to the rising patient population seeking expert diagnostic services.

By End User

Hospitals:

Hospitals constitute a significant segment of the biopsy system market, as they are equipped with specialized staff and advanced technologies necessary for conducting various biopsy procedures. The comprehensive care provided at hospitals, including immediate access to surgical teams and postoperative support, makes them the preferred choice for many patients undergoing biopsies. As the prevalence of cancer diagnoses rises, hospitals are likely to increase their biopsy throughput, further driving market growth. Additionally, the integration of advanced diagnostic technologies in hospitals enhances the accuracy and effectiveness of biopsy procedures.

Diagnostic Centers:

Diagnostic centers are essential end-users of biopsy systems, offering dedicated services for diagnostic testing and imaging. These centers often provide a range of biopsy procedures, allowing for quick turnaround times and efficient patient management. With the increasing demand for timely and accurate diagnostic services, diagnostic centers are expanding their capabilities to include advanced biopsy techniques. The convenience and specialization offered by these centers are contributing to their growing prominence in the biopsy system market, as more patients seek accessible diagnostic options.

Specialty Clinics:

Specialty clinics play a critical role in the biopsy system market, focusing on specific areas such as oncology, dermatology, and urology. These clinics provide targeted services and have expertise in performing various biopsy procedures tailored to patient needs. The increasing incidence of cancer and other related diseases drives the demand for specialized diagnostic procedures offered by these clinics. As awareness of the importance of early detection continues to grow, specialty clinics are expected to expand their biopsy offerings, thus contributing significantly to market growth.

Research Institutes:

Research institutes are vital in the biopsy system market, as they engage in innovative research and development of new biopsy technologies and methodologies. These organizations collaborate with hospitals and diagnostic centers to advance the field of cancer diagnostics and improve patient outcomes. The focus on precision medicine and the need for accurate diagnostic tools is driving research efforts in this segment. As funding for cancer research increases and new technologies are developed, research institutes are expected to play an even more significant role in shaping the future of biopsy systems.

Pharmaceutical Companies:

Pharmaceutical companies are becoming increasingly involved in the biopsy system market, as they recognize the importance of accurate diagnostics in drug development and personalized medicine. These companies often utilize biopsy systems to collect tissue samples necessary for clinical trials and research studies. The growing focus on targeted therapies and the need for biomarker identification are driving the demand for biopsy systems among pharmaceutical companies. As the pharmaceutical industry continues to evolve, the collaboration between biopsy technology providers and drug developers is expected to grow, further supporting market expansion.

By Region

The biopsy system market is witnessing substantial growth across various regions, driven by differing healthcare infrastructures, cancer incidences, and technological advancements. North America dominates the market due to its advanced healthcare systems, high prevalence of cancer, and significant investment in research and development. The region accounted for approximately 40% of the global market share in 2025, and it is projected to grow at a CAGR of 7.5% through 2035. The increasing adoption of advanced biopsy techniques and growing demand for early cancer detection are key factors contributing to this growth. Moreover, a robust pipeline of innovative biopsy technologies is expected to enhance the regional market.

Europe and Asia Pacific follow North America in terms of market share. Europe is expected to capture around 25% of the global market, driven primarily by rising cancer incidences and an aging population. The introduction of new diagnostic technologies and increasing healthcare expenditures are also propelling growth in this region. Meanwhile, the Asia Pacific market is projected to grow at a significant CAGR of 8.0%, driven by increasing healthcare accessibility, rising awareness about cancer screening, and technological advancements in biopsy procedures. In Latin America and the Middle East & Africa, the biopsy system market is also anticipated to grow, albeit at a slower pace, primarily due to varying healthcare infrastructure and economic factors affecting healthcare delivery.

Opportunities

The biopsy system market is rife with opportunities for growth and innovation. One significant opportunity lies in the increasing implementation of liquid biopsy technologies, which offer a less invasive alternative to traditional biopsy methods. As research continues to demonstrate the efficacy of liquid biopsies in detecting various cancers, there is a growing interest from both healthcare providers and patients. This trend is likely to encourage further investment in this area, leading to the development of more sophisticated liquid biopsy procedures that can help in early cancer detection and monitoring treatment effectiveness. Additionally, as regulatory frameworks evolve to support these innovations, the market potential for liquid biopsies is expected to expand significantly.

Another promising opportunity in the market is the integration of advanced technologies such as artificial intelligence (AI) and machine learning into biopsy systems. These technologies can enhance the accuracy and efficiency of biopsy analysis, enabling healthcare providers to make more informed decisions regarding patient care. By automating image analysis and providing predictive analytics, AI can help clinicians identify cancerous tissues with greater precision, thereby improving diagnosis and treatment outcomes. As healthcare systems increasingly adopt these digital solutions, there will be a strong demand for innovative biopsy systems that leverage AI capabilities, presenting a substantial opportunity for growth in the industry.

Threats

One of the primary threats facing the biopsy system market is the rising cost of healthcare, which may limit patient access to necessary diagnostic procedures. As healthcare expenditures continue to climb, patients may be less likely to undergo biopsies, particularly in regions with limited insurance coverage or high out-of-pocket costs. This financial barrier could deter early detection of cancer, ultimately impacting patient outcomes and reducing the demand for biopsy systems. Additionally, the introduction of more effective non-invasive diagnostic alternatives could further threaten the growth of traditional biopsy systems, as patients and healthcare providers may opt for these less invasive options whenever possible.

Another significant threat is the evolving regulatory landscape surrounding medical devices and diagnostics. Stricter regulations and prolonged approval processes for new biopsy technologies can hinder innovation and slow the introduction of novel products to the market. As companies invest substantial resources in research and development, any delays in obtaining regulatory approvals could impact their competitiveness and profitability. Additionally, market players must navigate the complexities of compliance with varying regulations in different regions, which adds an extra layer of challenge for companies seeking to expand their operations and offerings.

Competitor Outlook

• Boston Scientific Corporation
• Medtronic plc
• Thermo Fisher Scientific Inc.
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• Stryker Corporation
• Fujifilm Holdings Corporation
• Siemens Healthineers AG
• Olympus Corporation
• GE Healthcare
• Canon Medical Systems Corporation
• Abbott Laboratories
• Roche Holding AG
• Exact Sciences Corporation
• Laboratory Corporation of America Holdings

The biopsy system market is competitive, characterized by the presence of numerous multinational companies and innovative startups striving for technological advancements and market share. Major players, such as Boston Scientific and Medtronic, are focusing on expanding their product portfolios through research and development, mergers, and acquisitions. As a result, these companies have developed sophisticated biopsy systems that enhance diagnostic accuracy and patient experience. Additionally, the growing trend towards minimally invasive procedures is prompting companies to innovate and incorporate advanced technologies into their offerings, ensuring they remain competitive in an increasingly demanding market.

Another key player in this space is Thermo Fisher Scientific, which is renowned for its commitment to advancing life sciences through innovative diagnostic solutions. The company invests heavily in research, aiming to develop cutting-edge biopsy technologies that are efficient and effective. Hologic, recognized for its leadership in women's health, has made significant strides in breast biopsy technologies, thereby catering to a significant market segment. By leveraging their strong expertise in diagnostics and imaging, these companies are well-positioned to address the evolving needs of healthcare providers and patients alike.

Moreover, players like Hologic and Exact Sciences are at the forefront of liquid biopsy technology, which has transformed cancer diagnostics. Their ongoing research and development efforts focus on enhancing the sensitivity and specificity of liquid biopsies to ensure they become a standard diagnostic tool in oncology. As the competition intensifies, these companies are also investing in strategic partnerships and collaborations to accelerate innovation and expand their market presence. Such collaborations often lead to the sharing of expertise, resources, and technologies, further enhancing their competitive advantages in the biopsy system market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GE Healthcare
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Holding AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Abbott Laboratories
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Olympus Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Stryker Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Exact Sciences Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Boston Scientific Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Fujifilm Holdings Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Canon Medical Systems Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Laboratory Corporation of America Holdings
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biopsy System Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Specialty Clinics
    • 6.1.4 Research Institutes
    • 6.1.5 Pharmaceutical Companies
  • 6.2 Biopsy System Market, By Application
    • 6.2.1 Breast Biopsy
    • 6.2.2 Prostate Biopsy
    • 6.2.3 Lung Biopsy
    • 6.2.4 Liver Biopsy
    • 6.2.5 Skin Biopsy
  • 6.3 Biopsy System Market, By Product Type
    • 6.3.1 Needle Biopsy
    • 6.3.2 Surgical Biopsy
    • 6.3.3 Liquid Biopsy
    • 6.3.4 Robotic Biopsy
    • 6.3.5 MRI-Guided Biopsy
  • 6.4 Biopsy System Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Centers
    • 6.4.3 Cancer Research Institutes
    • 6.4.4 Ambulatory Surgical Centers
    • 6.4.5 Specialty Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Biopsy System Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biopsy System market is categorized based on

By Product Type

• Needle Biopsy
• Surgical Biopsy
• Liquid Biopsy
• Robotic Biopsy
• MRI-Guided Biopsy

By Application

• Breast Biopsy
• Prostate Biopsy
• Lung Biopsy
• Liver Biopsy
• Skin Biopsy

By Distribution Channel

• Hospitals
• Diagnostic Centers
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Specialty Clinics

By End User

• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Research Institutes
• Pharmaceutical Companies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Medtronic plc
• Thermo Fisher Scientific Inc.
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• Stryker Corporation
• Fujifilm Holdings Corporation
• Siemens Healthineers AG
• Olympus Corporation
• GE Healthcare
• Canon Medical Systems Corporation
• Abbott Laboratories
• Roche Holding AG
• Exact Sciences Corporation
• Laboratory Corporation of America Holdings